Workflow
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
RevvityRevvity(US:RVTY) ZACKSยท2025-04-28 14:31

Core Insights - Revvity (RVTY) reported revenue of $664.76 million for the quarter ended March 2025, reflecting a 2.3% increase year-over-year and a surprise of +0.39% over the Zacks Consensus Estimate of $662.17 million [1] - The company's EPS for the quarter was $1.01, up from $0.98 in the same quarter last year, resulting in an EPS surprise of +5.21% compared to the consensus estimate of $0.96 [1] Revenue and Earnings Performance - Organic revenue growth in Life Sciences was 2%, below the average estimate of 6.1% from three analysts [4] - Total organic revenue growth was reported at 4%, exceeding the average estimate of 3.6% from three analysts [4] - Organic revenue growth in Diagnostics was 5%, significantly higher than the average estimate of 1.5% from three analysts [4] Sales Metrics - Net Sales in Life Sciences reached $340.40 million, slightly above the average estimate of $338.13 million from three analysts, with a year-over-year change of +12.3% [4] - Net Sales in Diagnostics were reported at $324.37 million, slightly below the average estimate of $324.78 million from three analysts, representing a year-over-year decline of -6.6% [4] Stock Performance - Revvity's shares have returned -10.7% over the past month, compared to a -4.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]